CD274 and neoplasm: However, the assessment of PD‐L1 status in routine clinical practice remains suboptimal due to inconsistencies across clinical trials, including variations in diagnostic antibodies (clone 28‐8, 22C3, SP142, or SP263), immunohistochemical platforms/protocols (Dako vs. Ventana), cell types (tumor cells or immune cells), and thresholds [31].